Adenovirus 36 E4 orf 1 Protein Insulin Sensitivity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for diabetes and lipodystrophy lack effective methods to increase insulin sensitivity and adipocyte differentiation, leading to inadequate management of insulin resistance and fat storage issues.
Innovation Solution
The use of the Adenovirus type-36 E4 orf 1 protein or its encoding nucleic acid sequence to enhance insulin sensitivity and adipogenesis by promoting preadipocyte differentiation and glucose uptake in both adipose and skeletal muscle cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments for diabetes and lipodystrophy are used, then disease management is maintained at conventional levels, but insulin sensitivity and adipocyte differentiation remain insufficient
Solution Approach 1:
The patent converts the harmful effect of Ad-36 virus (which causes obesity) into a beneficial therapeutic effect by isolating and utilizing only the E4 orf 1 gene product. This gene product stimulates adipocyte differentiation and improves insulin sensitivity without causing the harmful obesity associated with whole virus infection, thus converting a pathogen into a therapeutic agent
Solution Approach 2:
The patent extracts the specific E4 orf 1 gene from the Ad-36 virus genome and uses only this isolated genetic element. By taking out just the beneficial gene responsible for adipocyte differentiation while leaving behind other viral components that cause harm, the invention achieves therapeutic effects without side effects
2Productivity
If Adenovirus type-36 E4 orf 1 protein is used to enhance insulin sensitivity and adipogenesis, then preadipocyte differentiation and glucose uptake are significantly improved, but the complexity of the treatment approach increases
Solution Approach 1:
The patent extracts and uses only the essential E4 orf 1 gene product, eliminating the need for complex viral delivery systems or combination therapies. This simplification maintains high productivity in adipocyte differentiation while reducing treatment complexity compared to using whole viruses or multiple gene products
Solution Approach 2:
The patent changes the fundamental parameter of treatment from using whole viruses or complex drug regimens to using a single purified protein product (E4 orf 1). This parameter change simplifies the treatment protocol while maintaining or enhancing the biological activity needed for adipocyte differentiation and insulin sensitivity improvement
Data Source
AI summary
Expression of the E4 orf 1 gene of Ad-36 alone has been discovered to be responsible for the increased insulin sensitivity observed in Ad-36 infected animals, including increased adipogenesis. Ad-36 E4 orf 1 protein can be used to increase insulin sensitivity and ameliorate diabetes. Additionally, drugs that mimic the action of Ad-36 E4 orf 1 protein could be found. Ad-36 E4 orf 1 could also be used to increase fat cells in lipodystrophy. We have also discovered that Ad-36 infection in human skeletal muscle cells increased differentiation and insulin independent glucose uptake. It is expected that infection with Ad-36 E4 orf 1 gene will also cause these effects.